Choo I H, Didisheim P, Doerge M L, Johnson M L, Bach M L, Melchert L M, Johnson W J, Taylor W F
Thromb Res. 1982;25(1-2):115-23. doi: 10.1016/0049-3848(82)90220-1.
A heparin assay method based on thrombin cleavage of a fluorogenic synthetic peptide has been evaluated in normal subjects, in patients with chronic renal disease on hemodialysis, and in patients with other disorders. The method has satisfactory accuracy, sensitivity, and reproducibility. In contrast to methods commonly used to monitor heparin therapy, it measures heparin directly and is uninfluenced by patient variables such as low antithrombin III. The method may provide valuable information in selected clinical settings such as cardiopulmonary bypass and in patients with chronic renal disease who receive heparin during hemodialysis or prior to surgery.
一种基于凝血酶切割荧光合成肽的肝素检测方法已在正常受试者、接受血液透析的慢性肾病患者以及患有其他疾病的患者中进行了评估。该方法具有令人满意的准确性、灵敏度和可重复性。与通常用于监测肝素治疗的方法不同，它直接测量肝素，不受诸如抗凝血酶III水平低等患者变量的影响。该方法可能在某些特定临床环境中提供有价值的信息，如体外循环以及在血液透析期间或手术前接受肝素治疗的慢性肾病患者。
